South Dakota Investment Council held its position in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,400 shares of the medical research company’s stock at the end of the 2nd quarter. South Dakota Investment Council’s holdings in Edwards Lifesciences Corporation were worth $5,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. South Texas Money Management Ltd. lifted its stake in Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after acquiring an additional 211,119 shares during the last quarter. Financial Counselors Inc. lifted its stake in Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after acquiring an additional 282 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock valued at $539,685,000 after acquiring an additional 850,168 shares during the last quarter. HPM Partners LLC acquired a new stake in Edwards Lifesciences Corporation in the first quarter valued at approximately $1,228,000. Finally, Vanguard Group Inc. lifted its stake in Edwards Lifesciences Corporation by 2.5% in the first quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock valued at $1,913,541,000 after acquiring an additional 505,725 shares during the last quarter. Hedge funds and other institutional investors own 82.36% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “South Dakota Investment Council Maintains Position in Edwards Lifesciences Corporation (EW)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/09/south-dakota-investment-council-maintains-position-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (EW) traded up 0.76% during trading on Friday, hitting $113.19. The company had a trading volume of 1,612,089 shares. The company’s 50 day moving average price is $114.46 and its 200-day moving average price is $108.19. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The stock has a market capitalization of $23.90 billion, a price-to-earnings ratio of 34.33 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company earned $0.76 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

A number of analysts have issued reports on EW shares. Vetr cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price for the company. in a research note on Monday, May 15th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Royal Bank Of Canada restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 30th. Bank of America Corporation boosted their price objective on shares of Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Finally, Jefferies Group LLC set a $115.00 price objective on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research note on Saturday, May 27th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $120.75.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total value of $2,119,917.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,641 shares of company stock valued at $15,013,114. 2.13% of the stock is currently owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.